NCT03226678已完成2 期
An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 8
- 主要终点
- Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity
研究概览
简要总结
This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age.
- •Weight < 125 Kg.
- •Subjects must have a primary diagnosis of wAIHA or CAD defined by the presence of hemolytic anemia and positive DAT for wAIHA (IgG) or CAD (C3).
- •Hemoglobin <11 g/dL.
- •Signs of hemolysis with abnormal values by any of the hemolytic markers:
- •Increased absolute reticulocyte count (above ULN)
- •Reduced haptoglobin (below LLN)
- •Increased lactase dehydrogenase (LDH) (above ULN)
- •Increased indirect bilirubin (above ULN)
- •Women of child-bearing potential (WOCBP) (defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study and 60 days after their last dose of study drug.
- •Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and 60 days after their last dose of study drug.
- •Able to provide documentary evidence of the following vaccinations within 2 years prior to screening:
- •Neisseria meningitides types A, C, W, Y and type B (administered as two separate vaccinations)
- •Streptococcus pneumoniae (Pneumococcal conjugate vaccine and Pneumococcal polysaccharide vaccine 23 [PCV13 and/or PPSV23, respectively])
- •Haemophilus influenzae Type B (Hib) vaccine
- •Subjects that do not have documentary evidence must be willing to receive any missing vaccinations as outlined below:
- •Neisseria meningitides types A, C, W, Y and type B must be administered prior to dosing on Day
- •A booster is administered after at least 8 weeks (Day 56; for both vaccinations).
- •Streptococcus pneumoniae PCV13 must be administered prior to dosing on Day 1 (see Section 12.2 for details). A PPSV23 booster is administered after at least 8 weeks (Day 56)
- •Haemophilus influenze Type B (Hib) must be administered prior to dosing on Day
- •Willing and able to give informed consent.
- •Specific for wAIHA: Relapsed from, did not respond or relapsed, or did not tolerate, at least one prior wAIHA treatment regimen (such as prednisone, rituximab).
排除标准
- •Prior treatment with rituximab within 90 days.
- •Deficiency of iron, folic acid and vitamin B12 prior to treatment phase
- •Abnormal liver function as indicated by a direct bilirubin above normal level, and/or an AST or ALT level > 2x upper limit of normal. Please note elevated indirect bilirubin due to hemolysis is not an exclusion criteria.
- •Elevated bilirubin not due to active hemolysis. Any elevation of bilirubin >ULN will require Sponsor review and approval for subject enrollment into the trial.
- •Active aggressive lymphoma requiring therapy or an active non-lymphatic malignant disease other than basal cell carcinoma or carcinoma in situ (CIS) of the cervix.
- •Presence or suspicion of active bacterial or viral infection, in the opinion of the Investigator, at screening or severe recurrent bacterial infections.
- •Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days prior to screening period.
- •Pregnant, breast-feeding, or intending to conceive during the course of the study, including the Post-Treatment Phase.
- •Inability to cooperate or any condition that, in the opinion of the investigator, could increase the subject's risk by participating in the study or confound the outcome of the study.
- •Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or > Class 2 Angina Pectoris or NYHA Heart Failure Class >2
- •QTcF > 470 ms
- •PR > 280 ms
- •Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities
研究组 & 干预措施
270mg or 360mg APL-2 administered subcutaneously daily (CAD)
Experimental
干预措施: APL-2 (Drug)
270mg or 360mg APL-2 administered subcutaneously daily (wAIHA)
Experimental
干预措施: APL-2 (Drug)
结局指标
主要结局
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity
时间窗: Part A:From first dose of study drug (Part A Day 1) up to 30days after last dose of study drug in Part A,approximately 366days Part B:From first dose of study drug (Part B Day 1) up to 56days after last dose of study drug in Part B,approximately 980days
TEAEs were defined as adverse events (AEs) that occurred after dosing on Day 1 and up to 56 days after the last dose of study drug. A treatment-related TEAE is defined as a TEAE with a relationship to study drug of probably, possibly, unlikely, or unrelated. A serious adverse event (SAE) is defined as any AE that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; was a congenital anomaly or birth defect. TEAEs were graded according to Common Terminology Criteria for Adverse Events v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.
次要结局
- Mean Change From Baseline in Hemoglobin at Weeks 48 and 132(Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132)
- Number of Subjects Who Received Red Blood Cell (RBC) Transfusions(From Day 1 up to Week 132)
- Mean Change From Baseline in Absolute Reticulocyte Count (ARC) at Weeks 48 and 132(Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132)
- Mean Change From Baseline in Lactate Dehydrogenase (LDH) at Weeks 48 and 132(Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132)
- Mean Change From Baseline in Haptoglobin at Weeks 48 and 132(Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132)
- Mean Change From Baseline in Indirect Bilirubin at Weeks 48 and 132(Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132)
- Maximum Observed Trough Serum Concentration (Ctrough,Max) of Pegcetacoplan(Pre-dose and 4 hours postdose on Day 1; pre-dose on Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 36, 40, 48, 60, 72, 84, 96, 108, 120 and 132)
- Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 48 and 132(Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132)
- Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score at Weeks 48 and 132(Part A: Baseline (Day 1 of Part A) and Week 48; Part B: Baseline (Day 1 of Part B) and Week 132)
研究者
研究点 (8)
Loading locations...
相似试验
招募中
1 期
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid TumorsSquamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaCervical Squamous Cell CarcinomaNCT06747585Alentis Therapeutics AG170
已完成
2 期
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)AcromegalyNCT03789656Crinetics Pharmaceuticals Inc.47
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ⅡMucopolysaccharidosis IIHunter SyndromeNCT05422482GC Biopharma Corp12
已完成
1 期
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid TumoursAdvanced Solid TumoursNCT04462952AstraZeneca6
Unknown
2 期
Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®Cystic FibrosisNCT02722122Protalix15